spacer
home > epc > spring 2002 > uk phase i/iia cros - the challenges ahead
PUBLICATIONS
European Pharmaceutical Contractor

UK Phase I/IIa CROs - The Challenges Ahead

The EU Clinical Trials Directive

The implementation of the EU Clinical Trials Directive across member states will undoubtedly bring about a 'levelling of the playing field' as Phase I/IIa contract research organisations (CROs) compete for early phase clinical trials from pharmaceutical and biotechnology companies. With the additional burden of the strength of the pound at present, Phase I/IIa CROs in the UK face increasing commercial competition from their European counterparts and those based in the US and Canada.

UK Phase I/IIa CROs are currently able to offer pharma and biotechnology companies - particularly those in North America - faster clinical trial 'start-up' times in the early development of their compounds, as these trials do not require notification or approval by the national regulatory agency.

The cost and time benefits (particularly for smaller start-up companies) has meant that the UK has had a distinct commercial edge in attracting such trials. Implementation of the EU Clinical Trials Directive will not only provide greater harmonisation across European member states in terms of ethical and regulatory processes and clinical trial supply manufacture, but will create a more level playing field between UK CROs and their European and North American competitors. As early phase trials in the UK will now require regulatory approval, a key commercial advantage has been removed.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Wayne Griffin, Managing Director of Acumen Pharmaceutical Services Ltd

Wayne Griffin is Managing Director of Acumen Pharmaceutical Services Ltd, an early phase product development CRO based in Manchester, UK. He has more than 20 years' experience of working in the pharmaceutical industry, gaining scientific and managerial experience spanning all aspects of clinical development within several companies.
After graduating from the University of Surrey in 1980 he undertook a PhD at the University of London's cardiothoracic unit at Brompton Hospital in London, where he conducted various clinical research projects in cardiology and respiratory medicine. Wayne was previously Director of Clinical Research at an international CRO, and co-founded Acumen Pharmaceutical Services Ltd in 1998.

spacer
Wayne Griffin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>

White Papers

High-tech Packaging for High-tech Medicine

West Pharmaceutical Services, Inc.

As more biologics and biosimilars come on to the global pharmaceutical market, they can and will present unique packaging and containment challenges. For materials that are sensitive to glass or that may require larger-dose volumes or custom configurations, cyclic olefin polymers may offer a solution. These novel materials for drug container closure systems can provide a needed alternative to traditional glass containment systems for advanced therapeutics.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement